Article Search

Improved Survival with Enzalutamide in Biochemically Recurrent Prostate Cancer

February 1, 2026

Overall survival was 78.9% in the combination group compared with 69.5% in the leuprolide-alone group (HR 0.60). Enzalutamide monotherapy resulted in an overall survival of 73.1%, which was not statistically significant. We were already aware of the progression-free survival benefit; now we have overall survival data. This case was also presented in the MOC questions, where the correct answer was to add enzalutamide for a patient with a rising PSA on an LHRH agonist without imaging evidence of disease.

Read More »

Molecular profile-based adjuvant treatment for women with high-intermediate risk endometrial cancer (PORTEC-4a): results of a randomised, open-label, phase 3, multicentre, non-inferiority trial

January 1, 2026

The PORTEC-4a phase-3 trial showed that using a molecular integrated risk profile to tailor adjuvant therapy after surgery for high-intermediate risk endometrial cancer is safe and effective, and it lets nearly half of patients with favorable profiles avoid any radiation without compromising local control.

Read More »

Nivolumab for Resected Stage III or IV Melanoma 9 Years

January 1, 2026

The 9-year CheckMate 238 data show that adjuvant Nivo maintains a significant recurrent-free survival (RFS) advantage over the International Prognostic Index (Ipi) (median 61.1 vs 24.2 months; 9-year RFS 44% vs 37%) without a statistically significant overall survival (OS) difference (69% vs 65% at 9 years). OS is similar but I think this may highlight the shift towards neoadjuvant immunotherapy (IO) and effective salvage therapies.

Read More »

Amivantamab Plus Lazertinib in Atypical EGFR-Mutated Advanced Non–Small Cell Lung Cancer: Results From CHRYSALIS-2

January 1, 2026

The CHRYSALIS-2, the cohort C analysis of patients with atypical EGFR mutations showed meaningful and durable activity. Atypical mutations can be difficult to deal with as a clinician, and having concrete data on these (S768I, L861Q and G719ZX) mutations gives assurance that this doublet is active. Overall response rate (ORR) was 52% and median progression-free survival (PFS) was 11.1 months in refractory patients and 19.5 months in the treatment-naive population.

Read More »

Efficacy and Safety of Neoadjuvant TQB2102 in Locally Advanced or Early Human Epidermal Growth Factor Receptor 2–Positive Breast Cancer: A Randomized, Open-Label, Multicenter, Phase II Trial

January 1, 2026

The QUIWI study used quizartinib, a FLT3 drug added to standard chemo induction/consolidation in FLT-negative acute myeloid leukemia (AML) patients. There was a meaningful overall survival (OS) improvement across all age and risk groups including the NPM1+ population. They purposefully used a higher dose to achieve what is felt to be off-target TKI activity in familiar pathways of KIT, PDGRF…etc.

Read More »

CD19 CAR T-Cell Therapy for Autoimmune Hemolytic Anemia

January 1, 2026

This is a remarkable proof-of-concept study—11 out of 11 patients with multi-refractory AIHA achieved complete remission after CD19 CART, with rapid Hb normalization and a median drug-free remission of 11.5 months. Toxicity was surprisingly manageable (mostly grade 1–2 cytokine release syndrome (CRS)), and the relapse biology pointing to BCMA+ long-lived plasma cells really sets up a rational next step with plasma cell–directed strategies.

Read More »

Keyword Search

  • Article Search

  • Cancer Types

  • Month Contributed

  • Show FCS Articles Only

  • Sort Order

  • Number of Posts